

# *International Diagnostic Technologies, Inc.*

121 Yancy Road, Madison, Alabama 35758 USA

Phone: (205) 895-9865 Fax: (205) 895-9865

Email: [drmadarasz@idtscience.com](mailto:drmadarasz@idtscience.com)

## **Breakthrough in technology will provide the world's first accurate, cost-effective, non-invasive glucose monitor.**

**Huntsville, AL – December, 2000** - International Diagnostic Technologies, Inc. (IDT) has patented a unique opto-electronic based technology (U.S. Patent No. 5,871,442 and pending foreign patents) that should provide diabetics with the world's first accurate, dependable, rapid and affordable means to painlessly monitor blood glucose levels. IDT's technology was developed by a small group of scientists, internationally known for their work in academia, with private industry, NASA and the Department of Defense. IDT's technology is built on unique proven scientific principles. IDT was founded to develop the device, which is called the Photonic Molecular Probe™ (PMP)™ as well as other cutting edge proprietary technologies.

The PMP™ technology has a wide variety of applications. IDT is focusing on blood glucose monitoring as the PMP's first application since the world's approximately 120 million diabetics have a critical need for non-invasive blood glucose monitoring. Treatment and control of diabetes is highly dependent on the frequent monitoring of blood glucose levels. Currently, there is no acceptable alternative to monitoring blood glucose levels other than drawing blood.

Previous attempts to develop a noninvasive means of monitoring blood glucose levels have been unsuccessful as the devices have all been variations of Near InfraRed (NIR) Absorption Spectroscopy.

IDT's patented PMP™ technology operates in several distinct physical modes interacting with light. Non-invasive blood monitoring with the PMP™

exploits the chiral-geometric asymmetry-properties of the target molecule, which influences the light in a process called Circular Dichroism (CD)-chiral absorption. CD provides a much richer source of information leading to unambiguous structural identification of the target molecule. Concurrent with CD is another chiral process called Optical Rotatory Power (OR). OR yields additional signal information complementing the information obtained from CD measurements.

IDT has a 20-month development plan to build the prototype device, complete the signal processing (using a unique proprietary statistical methodology) and perform clinical studies. IDT's scientists, legal council and business managers have an alliance with a premier optics lab, MetroLaser, Inc. ([www.metrolaserinc.com](http://www.metrolaserinc.com)), to build the device. Development of the prototype will begin as soon as the "right partner" is found to help with funding.

The glucose monitoring market is approximately \$3.5 Billion, annually. IDT's technology is also applicable to biological/chemical warfare monitoring, fermentation process control, blood assays for emergency medical care and illicit/licit drug monitoring.